IONIS PHARMACEUTICALS INC 8K

Ionis Pharmaceuticals reported second quarter 2026 results showing strong underlying revenue growth but an operating loss, early commercial momentum for newly approved TRYNGOLZA and DAWNZERA, a solid cash position, and multiple upcoming regulatory and clinical milestones while reaffirming 2026 guidance and a 2028 cash-flow breakeven goal.

On July 29, 2026, Ionis Pharmaceuticals, Inc. reported its financial results for the quarter and six months ended June 30, 2026, highlighting 56% and 69% underlying revenue growth versus the prior year (excluding a 2025 sapablursen upfront payment), increased operating expenses tied to commercialization of TRYNGOLZA and DAWNZERA and launch preparation for zilganersen, and a GAAP operating loss of $102 million for the quarter. The company emphasized the late-June FDA approval and early U.S. launch momentum of TRYNGOLZA for severe hypertriglyceridemia, continued ramp of DAWNZERA for hereditary angioedema, and maintained that it remains on track to achieve its 2026 financial guidance and a cash-flow breakeven target in 2028, supported by a $2.1 billion cash and short-term investment balance and ongoing partnered revenue from products such as SPINRAZA and WAINUA. Ionis also provided significant pipeline and regulatory updates, including completion of enrollment in the Phase 3 REVEAL trial for Angelman syndrome, progress toward potential 2026 approvals and launches for zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B, and mixed Phase 3 results from the CARDIO-TTRansform study of eplontersen in ATTR-CM, while outlining multiple key clinical, regulatory, and commercial milestones expected later in 2026.

Filing Facts

CIK

874015

Ticker

IONS

Form

8K

Source Type

fda

Accession

0001140361-26-029960

Alert Tier

6